Results (3967)
CABOCARE: Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Austria
Germany
EU PAS number:
EUPAS108004
First published:
23/04/2024
StudyOngoing
id.DRIVE (former COVIDRIVE) study of brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe
Austria
Belgium
Germany
Italy
Spain
EU PAS number:
EUPAS42328
First published:
23/04/2024
StudyOngoing
Retrospective Observational non-interventional chart review study of patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland (FINPAH)
Finland
EU PAS number:
EUPAS41732
First published:
23/04/2024
StudyOngoing
Characterization of the epidemiology, treatment patterns and burden of Pulmonary Hypertension Group 1 and 3 in France, Germany and the UK: a real-word evidence study (PHILD_RWE_FR_DE_UK)
France
Germany
United Kingdom
EU PAS number:
EUPAS105806
First published:
23/04/2024
StudyFinalised
Real-world comparative effectiveness of rivaroxaban versus heparin and phenprocoumon for the treatment and secondary prevention of venous thromboembolism (RECENT)
Germany
EU PAS number:
EUPAS36102
First published:
23/04/2024
StudyFinalised
Prospective, observational, non-interventional, multicenter study to investigate treatment outcomes and patient satisfaction of Enstilum® foam (calcipotriol/betamethasone aerosol foam) as topical treatment of adult patients with psoriasis under the routine practice in Korea
Korea, Republic of
EU PAS number:
EUPAS38883
First published:
23/04/2024
StudyOngoing
OTEZLA® Tablets Drug Use-Results Survey (CC-10004-PSOR-018)
Japan
EU PAS number:
EUPAS36684
First published:
23/04/2024
StudyFinalised
A post-marketing registry-based prospective cohort study of long-term safety of risankizumab in Denmark and Sweden
Denmark
Sweden
EU PAS number:
EUPAS39351
First published:
23/04/2024
StudyOngoing
An Observational Longitudinal Post-authorization Safety Study of STELARA® in the Treatment of Psoriasis and Psoriatic Arthritis: Analysis of Major Adverse Cardiovascular Events (MACE) using Swedish National Health Registers (QUANTIFY STELARA MACE)
Sweden
EU PAS number:
EUPAS49873
First published:
23/04/2024
StudyFinalised
Risk of serious infections with bDMARDs in psoriasis/psoriatic arthritis patients: a large-scale cohort study using the Italian VALORE Project distributed database
Italy
EU PAS number:
EUPAS105426
First published:
23/04/2024
StudyOngoing
Real-world evaluation of effectiveness, persistence and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.
Australia
EU PAS number:
EUPAS39635
First published:
23/04/2024
StudyFinalised
Characterizing Otezla Use and Exposure Among Pregnant Women (20220012)
United States
EU PAS number:
EUPAS46267
First published:
23/04/2024
StudyFinalised
Retrospective Post-Marketing Safety Surveillance Study of Tofacitinib in Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA)
Canada
EU PAS number:
EUPAS46286
First published:
23/04/2024
StudyFinalised
REal Life Safety and effectiveness of tofAcitinib in comparison to TNF InhibitOrs using the French National Healthcare Database (RELATION)
France
EU PAS number:
EUPAS41054
First published:
23/04/2024
StudyOngoing
Drug utilisation study of Radium 223 under routine clinical practice in Europe (DIRECT)
Denmark
Germany
Netherlands
EU PAS number:
EUPAS37163
First published:
23/04/2024
StudyFinalised
Retrospective non-interventional chart review study of the clinical outcomes of guselkumab in the treatment of Finnish patients with plaque psoriasis (FINGUS)
Finland
EU PAS number:
EUPAS39376
First published:
23/04/2024
StudyFinalised
A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ (Tixagevimab/Cilgavimab) During Pregnancy (O-STEREO Study)
Canada
France
United States
EU PAS number:
EUPAS49565
First published:
23/04/2024
StudyPlanned
TAK-771-4004: Maternal and Infant Characteristics and Outcomes Following Exposure to HyQvia During Pregnancy: A Case Series Study Based on US Claims Data
United States
EU PAS number:
EUPAS103800
First published:
23/04/2024
StudyFinalised
Assesing the Safety of Antihypertensive medication in Pregnancy (ASAP)
Spain
EU PAS number:
EUPAS104849
First published:
23/04/2024
StudyOngoing
International Registry of Coronavirus Exposure in Pregnancy (IRCEP)
Argentina
Australia
Austria
Belgium
Brazil
Canada
Chile
Colombia
Denmark
France
Germany
Ghana
Greece
India
Ireland
Israel
Italy
Japan
Kenya
Mexico
Netherlands
New Zealand
Nigeria
Pakistan
Portugal
Russian Federation
South Africa
Spain
United Kingdom
United States
EU PAS number:
EUPAS37360
First published:
23/04/2024
StudyFinalised
Post-Authorisation Safety Study (PASS) of CLAIRYG® (Human normal immunoglobulin for intravenous use) in children under 12 years treated for primary immunodeficiency (PID) or immune thrombocytopenic purpura (ITP) (IGNGPASSP)
France
EU PAS number:
EUPAS33320
First published:
23/04/2024
StudyFinalised
A Registry of Patients with Biallelic Pro Opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), or Leptin Receptor (LEPR) Deficiency Obesity, or Bardet-Biedl Syndrome (BBS), Treated with Setmelanotide
France
Germany
Italy
Netherlands
Spain
United Kingdom
United States
EU PAS number:
EUPAS48822
First published:
23/04/2024
StudyPlanned
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada®) for HIV Pre-Exposure Prophylaxis (PrEP): A Pooled Observational Study
Austria
Benin
Brazil
Canada
Denmark
Ecuador
France
Germany
Ireland
Italy
Kenya
Netherlands
Peru
South Africa
Spain
Thailand
Uganda
United Kingdom
United States
Zimbabwe
EU PAS number:
EUPAS24332
First published:
23/04/2024
StudyFinalised
Safety and Effectiveness of Piperacillin/Tazobactam (Zosyn®) in the Treatment of Pediatric Hospital Acquired Pneumonia (HAP): A Retrospective Cohort Study
United States
EU PAS number:
EUPAS8352
First published:
23/04/2024
StudyFinalised
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
Belgium
France
Germany
Italy
Netherlands
Sweden
Switzerland
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS43201
First published:
23/04/2024
StudyOngoing
Exposure to SSRI/SNRI and depression in pregnancy and long-term childhood outcomes: the effect of modifying factors
Belgium
Croatia
Denmark
Finland
France
Germany
Ireland
Italy
Malta
Netherlands
Poland
Réunion
Spain
Sweden
Switzerland
Ukraine
United Kingdom
EU PAS number:
EUPAS43416
First published:
23/04/2024
StudyOngoing
Pregnancy protection and pregnancies in women of reproductive age on ACE-Inhibitors (ACEi), Angiotensin Receptor Blockers (ARB), statins or anti-diabetic medications: an observational study in primary care.
United Kingdom
EU PAS number:
EUPAS106500
First published:
23/04/2024
StudyPlanned
Cohort Event Monitoring of safety of COVID-19 vaccines in special populations (pregnant and lactating women, children and adolescents, immunocompromised, people with history of allergy, people with prior SARS-CoV-2 infection) (Covid-Vaccine-Monitor CVM)
Ireland
Italy
Netherlands
Portugal
Romania
Slovakia
Spain
Switzerland
EU PAS number:
EUPAS42504
First published:
23/04/2024
StudyFinalised
Pregistry International Pregnancy Exposure Registry (PIPER)
Canada
Nigeria
Philippines
South Africa
United Kingdom
United States
EU PAS number:
EUPAS46841
First published:
23/04/2024
StudyPlanned
Assessment of Pregnancy Outcomes in Women Exposed to Modafinil/Armodafinil: Pregnancy Database Study
France
United States
EU PAS number:
EUPAS43538
First published:
23/04/2024
StudyOngoing
Comprehensive Analysis of Clinical Parameters That May Inform the Choice of Dose Regimen for Carfilzomib 20/27mg/m2 or 20/56mg/m2 With and Without Dexamethasone (20200381)
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
China
Czechia
Denmark
Finland
France
Germany
Hungary
Israel
Italy
Japan
Korea, Republic of
Netherlands
New Zealand
Norway
Poland
Romania
Russian Federation
Serbia
Slovakia
Spain
Sweden
Taiwan
Thailand
Türkiye
Ukraine
United Kingdom
United States
EU PAS number:
EUPAS37838
First published:
23/04/2024
StudyFinalised
Non-interventional Post-authorization Safety Study (PASS) of Patients Treated with Idecabtagene Vicleucel (ide-cel, BB2121) for Multiple Myeloma (MM) in the Postmarketing Setting (BB2121-MM-006)
Austria
Belgium
Croatia
Czechia
Denmark
Finland
France
Germany
Greece
Italy
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS45152
First published:
23/04/2024
StudyOngoing
Non-Interventional Post-Authorisation Safety Study (PASS) survey to evaluate the effectiveness of the Isatuximab Educational Materials, to minimise the Risk of Interference for blood typing (minor antigen) (positive indirect Coombs’ test).
Austria
France
Germany
Italy
Netherlands
Poland
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS46988
First published:
23/04/2024
StudyFinalised
A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study
Belgium
Brazil
China
Colombia
France
Germany
Greece
Israel
Italy
Mexico
Spain
Taiwan
Türkiye
United Kingdom
United States
EU PAS number:
EUPAS41735
First published:
23/04/2024
StudyFinalised
BLENREP Effectiveness and Safety in Multiple Myeloma (BEaMM) – Real-World Evidence on Patients Taking Belantamab Mafodotin in Europe (217240)
Austria
Belgium
Germany
Greece
Italy
Norway
Spain
EU PAS number:
EUPAS44701
First published:
23/04/2024
StudyOngoing
A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO)
Brazil
Canada
Czechia
France
Germany
Italy
Netherlands
Poland
Spain
United Kingdom
United States
EU PAS number:
EUPAS49827
First published:
23/04/2024
StudyPlanned
Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy
Finland
France
Germany
Greece
Italy
Portugal
Spain
EU PAS number:
EUPAS49271
First published:
23/04/2024
StudyPlanned
Retrospective Analysis of Second Primary Malignancies (SPM) Data From ASPIRE and ENDEAVOR Studies (20220146)
United States
EU PAS number:
EUPAS103648
First published:
23/04/2024
StudyOngoing
Prevalence of multiple myeloma
France
Germany
United Kingdom
EU PAS number:
EUPAS104328
First published:
23/04/2024
StudyFinalised
A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
Austria
Brazil
Germany
United States
EU PAS number:
EUPAS49218
First published:
23/04/2024
StudyOngoing